The Acibadem Hospitals Group

The Acibadem Hospitals Group specializes in advanced healthcare services, particularly in reproductive medicine, providing comprehensive solutions for infertility and related treatments. Founded in 1991, The Acibadem Hospitals Group operates primarily in Istanbul, Turkey, focusing on advanced medical services. It has undergone significant changes, including the acquisition by Khazanah Nasional Berhad, which completed in November 2013 for USD 252 mn, as part of a larger deal to enhance its healthcare offerings. The company has engaged in a total of 4 deals, with the most recent deal occurring on July 29, 2013.

Acibadem does not have publicly noted subsidiaries or a parent company. The founder's detailed history is not available. Acıbadem Healthcare Group specializes in advanced medical services, primarily focusing on assisted reproductive technologies through its Reproductive Medicine and Infertility Department. This segment offers comprehensive services designed to assist couples struggling with infertility, including egg fertilization, embryo selection, and transfer procedures.

The company employs state-of-the-art technologies such as pre-implantation genetic testing and cryopreservation for eggs, sperm, or embryos, enhancing the likelihood of successful pregnancies. Acıbadem's target clientele comprises couples globally, particularly those from regions facing high treatment costs or limited access to quality reproductive healthcare. In 2015, The Acibadem Hospitals Group reported a revenue of USD 746. 69 mn and an EBITDA of USD 133.

68 mn. The revenue generation is structured primarily through direct-to-consumer transactions related to its reproductive medical services, including various treatment plans that may encompass multiple procedures and ancillary services such as genetic testing. The Acibadem Hospitals Group plans to expand its services into new geographic regions, particularly targeting markets in Europe and the Middle East by 2025. The recent funding from Khazanah Nasional Berhad will be utilized to enhance their reproductive medicine offerings and expand their international patient base.

This growth strategy follows their recent acquisition and aims to solidify their position in the healthcare market, ensuring they remain competitive and accessible to a wider audience.